Johnson & Johnson to acquire Firefly Bio for US$1B to advance KRAS-targeted cancer treatments

USA—Johnson & Johnson has agreed to acquire Firefly Bio in an all-cash deal valued at US$1 billion, reinforcing its commitment to advancing precision oncology and expanding its pipeline of targeted cancer therapies.

The acquisition strengthens the company’s focus on next-generation treatment approaches for hard-to-treat solid tumours.

The deal integrates Firefly Bio’s experimental Firelink degrader-antibody conjugate platform into J&J’s oncology research and development portfolio, marking a significant step in its long-term strategy to enhance targeted drug delivery systems.

Focus on KRAS-driven cancers

A key driver of the acquisition is the growing need for improved therapies targeting cancers linked to KRAS mutations.

These genetic alterations are associated with several aggressive solid tumours and have historically been difficult to target with conventional drug approaches.

Patients with KRAS-driven cancers often face limited treatment options, and outcomes remain poor in many cases, underscoring the urgency for more effective and selective therapies in this space.

Firelink platform and targeted delivery

Firefly Bio’s Firelink platform is built on degrader-antibody conjugate (DAC) technology, which is designed to transport protein degraders directly into tumour cells.

This approach aims to improve precision by concentrating therapeutic activity within cancer cells while limiting exposure to healthy tissue.

Although the platform remains in the preclinical stage, it shows potential for application across multiple tumour types driven by KRAS mutations.

Researchers believe the DAC approach could help overcome key limitations seen in existing oncology treatments and broaden the range of druggable targets.

Leadership perspective

John Reed, executive vice-president of innovative medicine research and development at Johnson & Johnson, said KRAS has long been regarded as an “undruggable” target due to its complex biology.

He noted that patients with KRAS-driven cancers continue to face limited therapeutic options and often experience survival measured in months rather than years.

He further explained that the Firelink platform could help address these challenges by improving targeted delivery mechanisms while expanding J&J’s early-stage oncology pipeline.

Regulatory path and pipeline outlook

The companies expect the transaction to close later this year, subject to regulatory approvals and standard closing conditions.

However, they have not disclosed timelines for clinical development or potential regulatory submissions for Firefly Bio’s pipeline candidates.

Johnson & Johnson has maintained a strong presence in oncology research for more than 30 years, with capabilities spanning antibody engineering and targeted therapy development.

The integration of Firefly Bio’s platform is expected to enhance these strengths while broadening its innovation base across oncology and immunology research, including biologics and small-molecule programs.

In March 2026, the US Food and Drug Administration approved J&J’s Icotyde (icotrokinra) for plaque psoriasis, marking the first oral peptide therapy approved in the United States for this indication.